Wingate Wealth Advisors Inc. Acquires New Holdings in DaVita Inc. (NYSE:DVA)

Wingate Wealth Advisors Inc. acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 545 shares of the company’s stock, valued at approximately $82,000.

A number of other institutional investors have also recently bought and sold shares of DVA. Transcendent Capital Group LLC acquired a new position in DaVita during the third quarter valued at approximately $25,000. Blue Trust Inc. boosted its holdings in shares of DaVita by 56.4% in the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after buying an additional 119 shares during the period. Quarry LP acquired a new position in shares of DaVita in the third quarter valued at approximately $60,000. Versant Capital Management Inc boosted its holdings in shares of DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares during the period. Finally, ORG Wealth Partners LLC acquired a new position in shares of DaVita in the third quarter valued at approximately $97,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $173.63 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm’s fifty day moving average price is $160.79 and its two-hundred day moving average price is $156.75. DaVita Inc. has a 1 year low of $108.76 and a 1 year high of $179.60. The firm has a market capitalization of $14.24 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94.

Wall Street Analyst Weigh In

Separately, Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.